Yoon et al. [20] showed that heterogeneous HER2 amplification in oesophageal adenocarcinoma independently predicted worse disease-specific survival and overall survival compared to non-heterogeneous HER2 amplified tumours. Here, ERBB2 is linked to esophageal adenocarcinoma.